Vascular endothelial growth factor, matrix metalloproteinases, and cyclooxygenase-2 influence prognosis of uterine cervical cancer in young women

International Journal of Oncology

Volumn 31, Issue 3, 2007, Pages 531-536

  Noriyuki, Maiko ^a   Sumi, Toshiyuki ^a   Xu, Zhi ^a   Misugi, Fumiko ^a   Nobeyama, Hiroyuki ^a   Yoshida, Hiroyuki ^a   Matsumoto, Yoshinari ^a   Yasui, Tomoyo ^a   Honda, Ken Ichi ^a   Ishiko, Osamu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclooxygenase 2; Matrix metalloproteinases; Uterine cervical cancer; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; MATRILYSIN; VASCULOTROPIN A;

ADENOCARCINOMA; ADULT; AGE; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROGNOSIS; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37449033201     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.3.531     Document Type: Article

References (46)

1. Values estimated by the Population-based Cancer Registry Research Group (Chairperson : Hideki Tsukuma), supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan. Annual Report (2003).
2. Kasamatsu T and Nakamura H: Registration of gynecologic malignancy in Japan. Nippon Rinsho 62: 44-48, 2004.
3. Kashimura M, Kawagoe T, Matsuura Y and Toki N: Epidemiology of uterine cervix cancer. Nippon Rinsho 62: 57-60, 2004.
4. Vikkola T, Karkkainen M, Claesson-Welsh L and Alitalo K: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60: 203-212, 2000.
5. Keck PJ, Hauser SD, Krivi G, et al: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312, 1989.
6. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
7. Maglione D, Guerriero V, Viglietto AM, Delli-Bovi P and Persico MG: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Acad Sci USA 88: 9267-9271, 1991.
8. Olofsson B, Pajusola K, Kaipainen A, et al: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93: 2576-2581, 1996.
9. Joukov V, Pajusola K, Kaipainen A, et al: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 290-298, 1996.
10. Lee J, Gray A, Yuan J, Luoh SM, Avraham H and Wood WI: Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93: 1988-1992, 1996.
11. Achen MG, Jeltsch M, Kukk E, et al: Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95: 548-553, 1998.
12. Meyer M, Clauss M, Lepple-Wienhues A, et al: A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 18: 363-374, 1999.
13. Volm M, Koomagi R, Mattern J and Stammler G: Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Res 17: 99-103, 1997. (Pubitemid 27116651)
14. Volm M, Koomagi R and Mattern J: Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74: 64-68, 1997. (Pubitemid 27157857)
15. Yoshiji H, Gomez DE, Shibuya M and Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56: 2013-2016, 1996.
16. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR and Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727-4735, 1993. (Pubitemid 23304407)
17. Suzuki K, Hayashi N, Miyamoto Y, et al: Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56: 3004-3009, 1996.
18. Tomisawa M, Tokunaga T, Oshika Y, et al: Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 35: 133-137, 1999.
19. Olson TA, Mohanraj D, Carson LF and Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54: 276-280, 1994. (Pubitemid 24042123)
20. Guidi AJ, Abu Jawdeh G, Tognazzi K, Dvorak HF and Brown LF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 78: 454-460, 1996. (Pubitemid 26250531)
21. Cheng WF, Chen CA, Lee CN, Wie HF, Hsieh FJ and Hsieh CY: Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 96: 721-726, 2000.
22. Kodama J, Yoshinouchi M, Seki N, Hongo A, Miyagi Y and Kudo T: Angiogenesis and platelet-derived endothelial cell growth factor/thymidine phorylase expression in cervical cancer. Int J Oncol 15: 149-154, 1999.
23. Kodama J, Seki N, Tokumo K, Hongo A, Yoshinouchi M, Okuda H and Kudo T: Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer 35: 485-489, 1999.
24. Liotta LA and Kohn EC: The microenvironment of the tumor-host interface. Nature 411: 375-379, 2001.
25. Johnsen M, Lund LR, Romer J, Almholt K and Dano K: Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10: 667-671, 1998.
26. Davidson B, Goldberg I, Gotlieb WH, et al: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17: 799-808, 1999.
27. Kumar A, Collins HM, Scholefield JH and Watson SA: Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer. Br J Cancer 82: 960-965, 2000.
28. Nomura H, Sato H, Seiki M, Mai M and Okada Y: Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 55: 3263-3266, 1995.
29. Yoshizaki T, Sato H, Maruyama Y, Murono S, Furukawa M, Park CS and Seiki M: Increased expression of membrane type 1-matrix metalloproteinase in head and neck carcinoma. Cancer 79: 139-144, 1997. (Pubitemid 26425519)
30. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Hang SC and Hsu SM: Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 63: 6537-6542, 2003.
31. Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P and Foidart JM: High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 65: 209-213, 1996.
32. Smith WL, De Witt DL and Garavito RM: Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182, 2000.
33. Williams CS, Tsujii M, Reese J, Dey SK and DuBois RN: Host cyclooxygenase-2 modulated carcinoma growth. J Clin Invest 105: 1589-1594, 2000.
34. Elder DJ, Halton DE, Hague A and Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drug: independence from COX-2 protein expression. Cancer Res 3: 1679-1683, 1997.
35. Sumi T, Ishiko O, Yoshida H, Hyun Y, Nakagawa E, Hirai K, Matsumoto Y and Ogita S: Expression of cyclooxygenase-2 in ovarian mature cystic teratomas with malignant transformation. Int J Mol Med 8: 495-498, 2001.
36. Giles D, Janine S, Margaret H, Lesley-Ann M, Nigel S and Mitch D: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Cancer Res 9: 2651-2656, 2003. (Pubitemid 36842109)
37. Ryu HS, Chang KH, Yang HW, Kim MS, Kwon HC and Oh KS: High cyclooxygenase-2 expression in stage 1B cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 76: 320-325, 2000. (Pubitemid 30131501)
38. Kim YB, Kim GE, Cho NH, Pyo HY, Shim SJ, Chang SK, Park HC, Suh CO, Park TK and Kim BS: Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 95: 531-539, 2002. (Pubitemid 34810178)
39. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
40. Nakanishi T, Ishikawa H, Suzuki Y, Inoue T, Nakamura S and Kuzuya K: A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 79: 289-293, 2000.
41. Irie T, Kigawa J, Minagawa Y, Itamochi H, Sato S, Akeshima R and Terakawa N: Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 26: 464-467, 2000.
42. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT and Major F: Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 38: 352-357, 1990.
43. Gauthier P, Gore I, Shingleton HM, Soong SJ, Orr JW Jr and Hatch KD: Identification of histopathologic risk groups in stage IB squamous cell carcinoma of the cervix. Obstet Gynecol 66: 569-574, 1985.
44. Chung CK, Nahhas WA, Zaino R, Stryker JA and Mortel R: Histologic grade and lymph node metastasis in squamous cell carcinoma of the cervix. Gynecol Oncol 12: 348-354, 1981. (Pubitemid 12197405)
45. Misugi F, Sumi T, Okamoto E et al: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis. Int J Mol Med 16: 541-546, 2005.
46. Yamashita K, Azumano I, Mai M and Okada Y: Expression and tissue localization of matrix metalloproteinase-7 (matrilysin) in human gastric carcinomas. Int J Cancer 84: 470-477, 1999.